Research progress of Gd-EOB-DTPA-enhanced magnetic resonance imaging in the evaluation of biological behavior of hepatocellular carcinoma

doi:10.3969/j.issn.1674-8115.2022.01.020

Abstract

Abstract:

Hepatocellular carcinoma is the most common primary malignant tumor of liver tumors and ranked as the third leading cause of cancer death. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) is a new hepatocyte-specific contrast agent commonly used at present. Its sensitivity and specificity for the diagnosis of small hepatocellular carcinoma can both be over 90%. Early diagnosis of hepatocellular carcinoma can benefit patients clinically, but as hepatocellular carcinoma is a highly heterogeneous tumor, the tumor biological behavior is also a key factor affecting the prognosis. Gd-EOB-DTPA-enhanced magnetic resonance imaging (EOB-MRI) can provide relevant information about identification of molecular typing, evaluation of immune microenvironment, and prediction of microvascular invasion and postoperative recurrence in hepatocellular carcinoma. This article reviews the research progress of EOB-MRI in the evaluation of biological behavior of hepatocellular carcinoma to provide reference for the diagnosis and treatment of hepatocellular carcinoma.

Key words: hepatocellular carcinoma (HCC), gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA), magnetic resonance imaging (MRI), molecular classification, β-catenin, immune microenvironment, microvascular invasion (MVI), recurrence

CLC Number:

R445.2

Yihuan WANG, Ruokun LI, Huanhuan CHONG, Fuhua YAN. Research progress of Gd-EOB-DTPA-enhanced magnetic resonance imaging in the evaluation of biological behavior of hepatocellular carcinoma[J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2022, 42(1): 130-134.

TrendMD

References 44

1	FORNER A, REIG M, BRUIX J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127): 1301-1314.
2	LI J, WANG J, LEI L, et al. The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced multi-detector computed tomography in detecting hepatocellular carcinoma: a meta-analysis of eight prospective studies[J]. Eur Radiol, 2019, 29(12): 6519-6528.
3	KIERANS A S, KANG S K, ROSENKRANTZ A B. The diagnostic performance of dynamic contrast-enhanced MR imaging for detection of small hepatocellular carcinoma measuring up to 2 cm: a meta-analysis[J]. Radiology, 2016, 278(1): 82-94.
4	REBOUISSOU S, NAULT J C. Advances in molecular classification and precision oncology in hepatocellular carcinoma[J]. J Hepatol, 2020, 72(2): 215-229.
5	UENO A, MASUGI Y, YAMAZAKI K, et al. OATP1B3 expression is strongly associated with Wnt/β-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma[J]. J Hepatol, 2014, 61(5): 1080-1087.
6	KITAO A, ZEN Y, MATSUI O, et al. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR imaging: correlation with molecular transporters and histopathologic features[J]. Radiology, 2010, 256(3): 817-826.
7	KITAO A, MATSUI O, YONEDA N, et al. Gadoxetic acid-enhanced MR imaging for hepatocellular carcinoma: molecular and genetic background[J]. Eur Radiol, 2020, 30(6): 3438-3447.
8	CHEN J, WU Z, XIA C, et al. Noninvasive prediction of HCC with progenitor phenotype based on gadoxetic acid-enhanced MRI[J]. Eur Radiol, 2020, 30(2): 1232-1242.
9	CHOI S Y, KIM S H, PARK C K, et al. Imaging features of gadoxetic acid-enhanced and diffusion-weighted MR imaging for identifying cytokeratin 19-positive hepatocellular carcinoma: a retrospective observational study[J]. Radiology, 2018, 286(3): 897-908.
10	WANG W, GU D, WEI J, et al. A radiomics-based biomarker for cytokeratin 19 status of hepatocellular carcinoma with gadoxetic acid-enhanced MRI[J]. Eur Radiol, 2020, 30(5): 3004-3014.
11	OURA K, MORISHITA A, TANI J, et al. Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: a review[J]. Int J Mol Sci, 2021, 22(11): 5801.
12	CHEN S, FENG S, WEI J, et al. Pretreatment prediction of immunoscore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging[J]. Eur Radiol, 2019, 29(8): 4177-4187.
13	GALON J, MLECNIK B, BINDEA G, et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours[J]. J Pathol, 2014, 232(2): 199-209.
14	GABRIELSON A, WU Y, WANG H, et al. Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC[J]. Cancer Immunol Res, 2016, 4(5): 419-430.
15	RUIZ DE GALARRETA M, BRESNAHAN E, MOLINA-SÁNCHEZ P, et al. β-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma[J]. Cancer Discov, 2019, 9(8): 1124-1141.
16	KUDO M. Gd-EOB-DTPA-MRI could predict WNT/β-catenin mutation and resistance to immune checkpoint inhibitor therapy in hepatocellular carcinoma[J]. Liver Cancer, 2020, 9(5): 479-490.
17	SPRANGER S, BAO R Y, GAJEWSKI T F. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity[J]. Nature, 2015, 523(7559): 231-235.
18	HARDING J J, NANDAKUMAR S, ARMENIA J, et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies[J]. Clin Cancer Res, 2019, 25(7): 2116-2126.
19	KUBO A, SUDA G, KIMURA M, et al. Characteristics and lenvatinib treatment response of unresectable hepatocellular carcinoma with iso-high intensity in the hepatobiliary phase of EOB-MRI[J]. Cancers, 2021, 13(14): 3633.
20	SUN L, MU L W, ZHOU J, et al. Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma[J]. Cancer Immunol Immunother, 2021: 1-14.
21	HECTORS S J, LEWIS S, BESA C, et al. MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma[J]. Eur Radiol, 2020, 30(7): 3759-3769.
22	RENZULLI M, BROCCHI S, CUCCHETTI A, et al. Can current preoperative imaging be used to detect microvascular invasion of hepatocellular carcinoma? [J]. Radiology, 2016, 279(2): 432-442.
23	MIN J H, LEE M W, PARK H S, et al. Interobserver variability and diagnostic performance of gadoxetic acid-enhanced MRI for predicting microvascular invasion in hepatocellular carcinoma[J]. Radiology, 2020, 297(3): 573-581.
24	LEE S, KIM S H, LEE J E, et al. Preoperative gadoxetic acid-enhanced MRI for predicting microvascular invasion in patients with single hepatocellular carcinoma[J]. J Hepatol, 2017, 67(3): 526-534.
25	RHEE H, AN C, KIM H Y, et al. Hepatocellular carcinoma with irregular rim-like arterial phase hyperenhancement: more aggressive pathologic features[J]. Liver Cancer, 2019, 8(1): 24-40.
26	FAN Y F, YU Y X, WANG X M, et al. Texture analysis based on Gd-EOB-DTPA-enhanced MRI for identifying vessels encapsulating tumor clusters (VETC)-positive hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2021, 8: 349-359.
27	HONG S B, CHOI S H, KIM S Y, et al. MRI features for predicting microvascular invasion of hepatocellular carcinoma: a systematic review and meta-analysis[J]. Liver Cancer, 2021, 10(2): 94-106.
28	YANG L, GU D, WEI J, et al. A radiomics nomogram for preoperative prediction of microvascular invasion in hepatocellular carcinoma[J]. Liver Cancer, 2019, 8(5): 373-386.
29	FENG S T, JIA Y, LIAO B, et al. Preoperative prediction of microvascular invasion in hepatocellular cancer: a radiomics model using Gd-EOB-DTPA-enhanced MRI[J]. Eur Radiol, 2019, 29(9): 4648-4659.
30	CHONG H H, YANG L, SHENG R F, et al. Multi-scale and multi-parametric radiomics of gadoxetate disodium-enhanced MRI predicts microvascular invasion and outcome in patients with solitary hepatocellular carcinoma ≤ 5 cm[J]. Eur Radiol, 2021, 31(7): 4824-4838.
31	WEI J W, JIANG H Y, ZENG M S, et al. Prediction of microvascular invasion in hepatocellular carcinoma via deep learning: a multi-center and prospective validation study[J]. Cancers, 2021, 13(10): 2368.
32	CHOI J W, LEE J M, KIM S J, et al. Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR images and their value as an imaging biomarker[J]. Radiology, 2013, 267(3): 776-786.
33	JOO I, LEE J M. Recent advances in the imaging diagnosis of hepatocellular carcinoma: value of gadoxetic acid-enhanced MRI[J]. Liver Cancer, 2016, 5(1): 67-87.
34	LEE D H, LEE J M, LEE J Y, et al. Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MRI: risk of HCC recurrence after radiofrequency ablation[J]. J Hepatol, 2015, 62(5): 1122-1130.
35	TOYODA H, KUMADA T, TADA T, et al. Non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of outcomes for early-stage HCC[J]. Hepatol Int, 2015, 9(1): 84-92.
36	GRANATA V, FUSCO R, SETOLA S V, et al. Microvascular invasion and grading in hepatocellular carcinoma: correlation with major and ancillary features according to LIRADS[J]. Abdom Radiol (NY), 2019, 44(8): 2788-2800.
37	AHN S J, KIM J H, PARK S J, et al. Hepatocellular carcinoma: preoperative gadoxetic acid-enhanced MR imaging can predict early recurrence after curative resection using image features and texture analysis[J]. Abdom Radiol (NY), 2019, 44(2): 539-548.
38	LEE S, KIM K W, JEONG W K, et al. Gadoxetic acid-enhanced MRI as a predictor of recurrence of HCC after liver transplantation[J]. Eur Radiol, 2020, 30(2): 987-995.
39	AN C, KIM M J. Imaging features related with prognosis of hepatocellular carcinoma[J]. Abdom Radiol (NY), 2019, 44(2): 509-516.
40	KIM A Y, SINN D H, JEONG W K, et al. Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma[J]. J Hepatol, 2018, 68(6): 1144-1152.
41	CALDERARO J, PETITPREZ F, BECHT E, et al. Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma[J]. J Hepatol, 2019, 70(1): 58-65.
42	WANG M D, LI C, LIANG L, et al. Early and late recurrence of hepatitis B virus-associated hepatocellular carcinoma[J]. Oncologist, 2020, 25(10): e1541-e1551.
43	JUNG S M, KIM J M, CHOI G S, et al. Characteristics of early recurrence after curative liver resection for solitary hepatocellular carcinoma[J]. J Gastrointest Surg, 2019, 23(2): 304-311.
44	CHONG H, GONG Y, PAN X, et al. Peritumoral dilation radiomics of gadoxetate disodium-enhanced MRI excellently predicts early recurrence of hepatocellular carcinoma without macrovascular invasion after hepatectomy[J]. J Hepatocell Carcinoma, 2021, 8: 545-563.

[1]	Yan-jie JI, Hao LUO, Hai-yan CAI, Xin-yu LIU, Shi-jia JIN, Shen-yue SU, Han-zhang XU, Hu LEI, Ying-li WU. Inhibition of CDDO-ME on ubiquitin-specific protease 2a activity and cell proliferation in triple negative breast cancer cells [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(8): 1025-1032.
[2]	Jia-shi ZHU, Hong LI, Jing-bo SHAO, Na ZHANG, Jing-wei YANG, Kai CHEN, Zhen WANG, Hui JIANG. A clinical study on treatment failure of childhood acute lymphoblastic leukemia [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(6): 764-769.
[3]	Ji-ping DING, Xiao-guang LI, Zhong-long LIU, Gang DENG, Yuan YAO, Yue HE. A case report of recurrent and metastatic tongue squamous cell carcinoma treated with salvage surgery combined with chemoradiotherapy and sequential immune checkpoint inhibitor [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(12): 1704-1708.
[4]	Ting QIU, Jing JIN, Yuan-yue CUI, Lei SONG, Xie LI, Ji-fang QU. A case report of fundus hemorrhage in recurrent acute myeloid leukemia [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(1): 123-125.
[5]	GAO Jing-ze, WU Xia. CXCL9 mRNA in ovarian tumor tissue and its relations with prognosis and characteristics of immune microenvironment [J]. , 2020, 40(4): 457-.
[6]	ZHU Zheng-yang, WANG Cheng, JIANG Chen-yi, ZHAO Fu-jun. Aberrant RNA N6-methyladenosine modification causes tumorigenesis, progression and metastasis of malignant tumorsaffecting cancer stem cells [J]. , 2020, 40(3): 385-.
[7]	YANG Tao, CHEN Jun, FANG Yi-ru. Advances in magnetic resonance imaging study of bipolar Ⅰdisorder [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(12): 1660-1664.
[8]	YUE Xiu-hui, KONG Wei-dan, REN Ji-liang, YUAN Ying#, TAO Xiao-feng#. Value of 3.0-T MR diffusion-weighted imaging combined with dynamic contrast-enhanced imaging in differentiating benign and malignant thyroid nodules [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(10): 1393-1397.
[9]	LI Xiao-min1, QU Yang1, WU Wen2, ZHAO Liang3, ZHANG Shao-ting3, HAO Yong-qiang2, DAI Ke-rong2, AI Song-tao1. Preliminary application of MR imaging-pathology co-localization by 3D printing box in pelvic tumor assessment [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(10): 1408-1413.
[10]	WANG Tao, ZHANG Chen-cheng, LI Dian-you, SUN Bo-min, FU Meng. Imaging law of postoperative electrode locations in deep brain stimulation for Parkinsons disease [J]. , 2020, 40(1): 64-.
[11]	JI Ying-ying, XUE Bin, HUANG Yue, ZHANG Jian-wei. Efficacy and safety of oral midazolam in combination with intranasal dexmedetomidine for paediatric magnetic resonance imaging sedation [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(08): 1098-1102.
[12]	DOU Min1, 2, ZHENG Ying-xia2, HAN Li2, ZHAO Qian1. Role and mechanism of PRMT4 in genesis and progression of gastric cancer [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(05): 609-618.
[13]	LU Yu-jie, JIN Ze-yu, LI Ya-fen, SHEN Kun-wei, CHEN Wei-guo, CHEN Xiao-song. Receptor status testing and its influence on following treatment selection in breast cancer patients with loco-regional recurrence [J]. , 2019, 39(9): 1071-.
[14]	CHEN Jun-zhao,ZHAO Zhan-lin,YAO Qin-ke,SHAO Chun-yi,FU Yao. Clinical observation on prevention of pterygium recurrence with bleomycin in pterygium surgery [J]. , 2019, 39(5): 510-.
[15]	RUAN Jing-jing, LU Qing, TANG Hui, ZHU Zhen-ya, FAN Yu, ZHAO Xin-xin, NIU Xiao-yin. Value of multi-parameter magnetic resonance imaging of cartilage in evaluating efficacy of adipose-derived mesenchymal progenitor cells on knee osteoarthritis [J]. , 2019, 39(12): 1409-.